Ablatherm-HIFU Featured in Eight Presentations at World Congress of Endourology (WCE) Ablatherm-HIFU Focal Treatment Advantages Showcased at First Montreal Conference on Focal Therapy LYON, France , Dec. 8, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
LYON, France , Aug. 17, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today provided an update regarding its Ablatherm-HIFU ( High Intensity Focused Ultrasound ) ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer.
LYON, France , March 20, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has completed its response to questions from the FDA regarding the Company's Ablatherm-HIFU Pre-Market Approval ("PMA") application, closing this step
Responds to Gastroenterology and Urology Devices Panel Vote on Ablatherm-HIFU for Treatment of Prostate Cancer LYON, France , Aug. 5, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today provided comments on the recent Gastroenterology and Urology
EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S. LYON, France , March 6, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the appointment of Noah J. Bartsch as Vice President of Global Medical, Regulatory, and